Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 (Aldesleukin) in CVID
DRKS00010424Phase 2Recruiting
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Jul 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in common variable immunodeficiency (CVID), sponsored by Universitätsklinikum Freiburg. Started Jul 2016; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on DRKS00010424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00010424.